Editas Medicine (EDIT) Tops Q4 EPS by 11c

Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.61), $0.11 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $12.5 million versus the consensus estimate of $4.29 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
• Bending Spoons S.p.A. (BSP) Tops Q2 EPS by 19c; offers guidance
• ADC Therapeutics SA (ADCT) Tops Q2 EPS by 11c